Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Neuregenix was founded in 2007 by Professor Martin Berry, Dr Zubair Ahmed and myself, three neuroscientists at the forefront of neurotrauma and neurodegeneration research, with an ambition to enhance the impact of our areas of research excellence. The last 11 years have confirmed and expanded that ambition.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Jiangsu Haosi Biotechnology Co., Ltd., established on 2017-06-14, Business scope includes biotechnology development,technical consulting,technology transfer,Technical extension services;Class I,Class II,Class III medical device research and development,Production;Instrumentation,Laboratory Equipment Sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after the approval of relevant departments) licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in D��sseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function.\nAs a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion.

BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.